Financials in USD. Standardized financial statements.
A compact view of how CBD Global Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Revenue? | $166,947 | $305,400 | $2.32M |
| Revenue Growth? | -45.3% | -86.8% | 0.0% |
| Cost of Revenue? | $125,948 | $492,461 | $883,892 |
| Gross Profit? | $40,999 | -$187,061 | $1.43M |
| Gross Margin? | +24.6% | -61.3% | +61.9% |
| Operating Expenses? | $2.73M | $2.39M | $3.75M |
| Operating Income? | -$2.74M | -$2.65M | -$2.37M |
| EBITDA? | -$4.05M | -$2.55M | -$4.75M |
| Income Before Tax | -$5.20M | -$8.93M | -$9.07M |
| Income Tax Expense | $590,910 | $0 | -$116,000 |
| Net Income? | -$5.25M | -$8.93M | -$8.96M |
| EPS? | $-0.15 | $-0.28 | $-0.53 |
| Diluted EPS? | $-0.15 | $-0.28 | $-0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality